4DMedical Secures Multi-Year Contracts Covering 10,000 Lung Scans in Brazil and Australia

Strategic Expansion into Brazil and Australia

4DMedical Limited (ASX – 4DX), a pioneer in respiratory imaging technology, has announced a series of significant agreements that will broaden the deployment of its lung health analysis software across two key international markets. The company’s collaborations with a leading global pharmaceutical company in Brazil, Royal Melbourne Hospital, and Spectrum Medical Imaging in Australia mark a decisive step in embedding advanced lung screening and diagnostic tools into frontline clinical practice.

In Brazil, 4DMedical has initiated a lung health screening program at Hospital Madre Teresa in Belo Horizonte, focusing on lung cancer detection alongside incidental findings such as coronary artery calcification and chronic obstructive pulmonary disease (COPD). This program, which aims to analyze up to 10,000 scans by August 2026, is set to expand nationally across multiple hospitals, reflecting a growing demand for sophisticated respiratory diagnostics in South America.

Pioneering Clinical Adoption in Australia

Back home, Royal Melbourne Hospital has become the first Australian public hospital and Academic Medical Centre to pilot 4DMedical’s comprehensive suite of lung ventilation and imaging software. This pilot, running through the end of 2025, integrates tools such as CT LVAS™, XV LVAS™, and Lung Texture Analysis to enhance clinical assessment of lung health, particularly within the framework of Australia’s National Lung Cancer Screening Program (NLCSP).

Complementing this, Spectrum Medical Imaging in New South Wales has entered a multi-year agreement to expand its use of 4DMedical’s technology stack. Already a provider of CT LVAS™, Spectrum will now incorporate additional modules including low-dose CT nodule detection and structural lung analysis, further enriching the diagnostic capabilities available to clinicians participating in the NLCSP. This partnership underscores a shared commitment to delivering precise, patient-centred respiratory care without the need for additional imaging equipment.

Technology Driving Early Detection and Better Outcomes

4DMedical’s software leverages artificial intelligence to transform standard CT scans into detailed functional insights, enabling earlier detection and more accurate monitoring of lung diseases. The integration of these tools into national screening programs represents a meaningful advance in respiratory healthcare, offering clinicians enhanced data to guide interventions and improve patient outcomes.

CEO Andreas Fouras highlighted the significance of these developments, noting the company’s commitment to Australian healthcare infrastructure and the promising expansion into South America. The ongoing FDA clearance process for their CT – VQ™ technology in the US adds further momentum to 4DMedical’s global growth trajectory.

As these partnerships mature, 4DMedical is poised to solidify its position as a leader in lung health diagnostics, driving innovation that bridges technology and clinical practice across continents.